Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To determine whether the combination of MM-302 plus trastuzumab is more effective than chemotherapy of physician’s choice (CPC) plus trastuzumab based on progression free survival (PFS) as assessed by an independent blinded review of tumor assessments.
Critère d'inclusion
- Locally Advanced/Metastatic HER2-Positive Breast Cancer